Misplaced Pages

This article includes a list of general references, but it lacks sufficient corresponding inline citations. Please help to improve this article by introducing more precise citations. (October 2021) (Learn how and when to remove this message)

Fungal pneumonia
H&E stain showing a fungal pneumonia (pulmonary aspergillosis)
Specialty	Infectious disease, respirology

Fungal pneumonia is an infection of the lungs by fungi. It can be caused by either endemic or opportunistic fungi or a combination of both. Case mortality in fungal pneumonias can be as high as 90% in immunocompromised patients, though immunocompetent patients generally respond well to anti-fungal therapy.

Signs and symptoms

Fungal pneumonia can present similarly to that of the common flu or other common illnesses. Symptoms often include fever, cough, headaches, rashes, muscle aches, and/or joint pain. This can lead to treatment being delayed or unsought altogether.

In a very small portion of people, fungal pneumonia can lead to chronic pneumonia, fungemia (presence of fungi in the blood), meningitis (infection of the meninges of the brain or spine), or even death. However, this is extremely rare and the vast majority of cases go untreated, unreported, or are asymptomatic (e.g. the infected person is not aware they are or were infected).

Causes

Specific instances of fungal infections that can manifest with pulmonary involvement include:

• Coccidioidomycosis, which begins with an often self-limited respiratory infection (also called "Valley fever" or "San Joaquin fever")
• Pneumocystis pneumonia, which typically occurs in immunocompromised people, especially AIDS
• Sporotrichosis — primarily a skin disease, but can involve the lungs as well
• Cryptococcus species can sometimes invade the lungs
• Aspergillosis, resulting in invasive pulmonary aspergillosis
• rarely, candidiasis has pulmonary manifestations in immunocompromised patients.
• Histoplasmosis or Spelunker's lung

Pathophysiology

Fungi typically enter the lung with inhalation of their spores, though they can reach the lung through the bloodstream if other parts of the body are infected. Also, fungal pneumonia can be caused by reactivation of a latent infection. Once inside the alveoli, fungi travel into the spaces between the cells and also between adjacent alveoli through connecting pores. This invasion triggers the immune system to respond by sending white blood cells responsible for attacking microorganisms (neutrophils) to the lungs. The neutrophils engulf and kill the offending organisms but also release cytokines which result in a general activation of the immune system. This results in the fever, chills, and fatigue common in bacterial and fungal pneumonia. The neutrophils and fluid leaked from surrounding blood vessels fill the alveoli and result in impaired oxygen transportation.

Diagnosis

Fungal pneumonia can be diagnosed in a number of ways. The simplest and cheapest method is to culture the fungus from a patient's respiratory fluids. However, such tests are not only insensitive but take time to develop which is a major drawback because studies have shown that slow diagnosis of fungal pneumonia is linked to high mortality. Microscopy is another method but is also slow and imprecise. Supplementing these classical methods is the detection of antigens. This technique is significantly faster but can be less sensitive and specific than the classical methods.

Treatment

Fungal pneumonia can be treated with antifungal drugs and sometimes by surgical debridement.

See also

• Pneumonia

References

1. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E (July 2007). "Invasive aspergillosis in the intensive care unit". Clin. Infect. Dis. 45 (2): 205–16. doi:10.1086/518852. PMID 17578780.
2. Bulpa P, Dive A, Sibille Y (October 2007). "Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease". Eur. Respir. J. 30 (4): 782–800. doi:10.1183/09031936.00062206. PMID 17906086.
3. Fungal Pneumonia: a silent epidemic | CDC PDF www.cdc.gov/fungal/pdf/cocci-fact-sheet-sw-us-508c.pdf
4. Morrell M, Fraser VJ, Kollef MH (September 2005). "Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality". Antimicrob. Agents Chemother. 49 (9): 3640–5. doi:10.1128/AAC.49.9.3640-3645.2005. PMC 1195428. PMID 16127033.
5. Denning, D (September 2008). "Webinar on fungal diagnostics" (PDF).

External links

• Media related to Fungal pneumonia at Wikimedia Commons
• Coccidioidomycosis

• Pneumonia
• Infectious diseases
• Fungal diseases